Tibra Equities Europe’s Neurogene NGNE Stock Holding History

Tibra Equities Europe’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,131	Closed	-$266K	–	241
2017 Q4	$266K	Buy	+1,131	New	+$265K	0.11%	117

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Tibra Equities Europe's NGNE Position: Q1 2018 in Review

Tibra Equities Europe sold out of Neurogene (NGNE) in Q1 2018, closing a stake of 1,131 shares — an estimated $266K sold.

Tibra Equities Europe first reported a position in NGNE in Q4 2017 and held it in 1 quarter. The position peaked at $266K in Q4 2017. 50 funds tracked by Wall St. Rank hold NGNE as of Q1 2018.

Tibra Equities Europe reported no remaining Neurogene position as of Q1 2018 after selling out during the quarter.
Tibra Equities Europe sold 1,131 Neurogene shares in Q1 2018, an estimated $266K.
Tibra Equities Europe first reported a position in Neurogene in Q4 2017 and held it in 1 quarter.
Tibra Equities Europe's Neurogene position peaked at $266K in Q4 2017.
50 funds tracked by Wall St. Rank held Neurogene as of Q1 2018.

Based on Tibra Equities Europe's 13F filing for Q1 2018, filed 11 May 2018.